Rising incidence of thromboembolism secondary to COVID-19 has become a global
concern, with several surveys reporting increased mortality rates. Thrombogenic potential of …

Background: Anticoagulation is generally used in hospitalized patients with coronavirus
disease 2019 (COVID-19) as thromboprophylaxis. However, results from different studies …

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to a worldwide
pandemic, and patients with the infection are referred to as having COVID‐19. Although …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …

Background Best practice for prevention, diagnosis, and management of venous
thromboembolism (VTE) in patients with coronavirus disease 2019 (COVID‐19) is unknown …

Abstract Introduction Coronavirus disease (COVID‐19) is associated with a high incidence
of thrombosis and mortality despite standard anticoagulant thromboprophylaxis. There is …

Many aspects of care such as management of hypercoagulable state in COVID-19 patients,
especially those admitted to intensive care units is challenging in the rapidly evolving …

Background Studies report hypercoagulability in coronavirus disease 2019 (COVID‐19),
leading many institutions to escalate anticoagulation intensity for thrombosis prophylaxis …

Background Hospitalized patients with COVID‐19 suffered initially from high rates of venous
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …